Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.
Department of Pediatric Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
BMC Nephrol. 2020 Aug 12;21(1):340. doi: 10.1186/s12882-020-02011-4.
MIRAGE syndrome is a recently discovered rare genetic disease characterized by myelodysplasia (M), infection (I), growth restriction (R), adrenal hypoplasia (A), genital phenotypes (G), and enteropathy (E), caused by a gain-of-function mutation in the SAMD9 gene. We encountered a girl with molecularly-confirmed MIRAGE syndrome who developed steroid-resistant nephrotic syndrome.
She was born at 33 weeks gestational age with a birth weight of 1064 g. She showed growth failure, mild developmental delays, intractable enteropathy and recurrent pneumonia. She was diagnosed as MIRAGE syndrome by whole exome sequencing and a novel SAMD9 variant (c.4615 T > A, p.Leu1539Ile) was identified at age four. Biopsied skin fibroblast cells showed changes in the endosome system that are characteristic of MIRAGE syndrome, supporting the genetic diagnosis. Proteinuria was noted at age one, following nephrotic syndrome at age five. A renal biopsy showed focal segmental glomerulosclerosis (FSGS) with immune deposits. Steroid treatment was ineffective. Because we speculated that her nephrosis was a result of genetic FSGS, we decided not to introduce immunosuppressive agents and instead started enalapril to reduce proteinuria. Although her proteinuria persisted, her renal function was normal at age eight.
This is the first detailed report of a MIRAGE syndrome patient with nephrotic syndrome. Because patients with MIRAGE syndrome have structural abnormalities in the endosomal system, we speculate that dysfunction of endocytosis in podocytes might be a possible mechanism for proteinuria.
MIRAGE 综合征是一种最近发现的罕见遗传性疾病,其特征为骨髓增生异常(M)、感染(I)、生长受限(R)、肾上腺发育不全(A)、生殖器表型(G)和肠病(E),由 SAMD9 基因突变引起。我们遇到了一位患有分子确诊的 MIRAGE 综合征的女孩,她患有激素抵抗性肾病综合征。
她在 33 周胎龄时出生,出生体重为 1064 克。她表现出生长发育迟缓、轻度发育迟缓、难治性肠病和反复肺炎。她在四岁时通过全外显子组测序和一种新的 SAMD9 变体(c.4615T> A,p.Leu1539Ile)被诊断为 MIRAGE 综合征。活检皮肤成纤维细胞显示出内体系统的变化,这是 MIRAGE 综合征的特征,支持遗传诊断。她在一岁时出现蛋白尿,五岁时出现肾病综合征。肾脏活检显示局灶节段性肾小球硬化症(FSGS)伴有免疫沉积物。激素治疗无效。因为我们推测她的肾病是遗传 FSGS 的结果,所以我们决定不引入免疫抑制剂,而是开始使用依那普利来减少蛋白尿。尽管她的蛋白尿持续存在,但她在八岁时肾功能正常。
这是首例详细报告 MIRAGE 综合征伴肾病综合征的患者。由于 MIRAGE 综合征患者的内体系统存在结构异常,我们推测足细胞内吞作用的功能障碍可能是蛋白尿的一种可能机制。